Under development with Seikagaku Corporation of Japan, anti-CD23 antibodies target the CD23 receptor on immune cells. Antibodies directed against this receptor selectively inhibit the production of ImmunoglobulinE (IgE), and so may provide new treatments for asthma and allergic disorders.
Clinical Trial Update
In February 2000 IDEC initiated a Phase I trial in allergic asthma to evaluate safety, tolerability and pharmacokinetics. IDEC’s partner in the study is Seikagaku Corporation.